Late HDV RNA relapse after peginterferon alpha‐based therapy of chronic hepatitis delta

Benjamin Heidrich, Cihan Yurdaydın, Gökhan Kabaçam, Boris A. Ratsch, Kalliopi Zachou, Birgit Bremer, George N. Dalekos, Andreas Erhardt, Fehmi Tabak, Kendal Yalcin, Selim Gürel, Stefan Zeuzem, Markus Cornberg, C.‐Thomas Bock, Michael P. Manns, Heiner Wedemeyer, HIDIT‐1 Study Group – 28 February 2014 – Interferon alpha is the only treatment option for hepatitis delta virus (HDV). Trials investigating the efficacy of pegylated interferon alpha (PEG‐IFNa) showed HDV RNA negativity rates of 25‐30% 24 weeks after therapy.

Effect of the pretransplant serum sodium concentration on outcomes following liver transplantation

Michael D. Leise, Byung Cheol Yun, Joseph J. Larson, Joanne T. Benson, Ju Dong Yang, Terry M. Therneau, Charles B. Rosen, Julie K. Heimbach, Scott W. Biggins, W. Ray Kim – 25 February 2014 – Hyponatremia is associated with an increased risk of mortality on the liver transplantation (LT) waiting list. Although the incorporation of the serum sodium (Na) level into the Model for End‐Stage Liver Disease score may reduce wait‐list mortality, concerns remain about a potential association between pre‐LT hyponatremia and decreased post‐LT survival.

Subscribe to